🚑 Nasdaq: NVCR | $12.60 (+2.61%) | Sep 8, 2025 Close ⚡🧠💹

NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

🎯 Trigger: Big Insider Buys

When the CEO Ashley Cordova scoops up 81,550 shares (~$1M) at $12.22 and the CFO Christoph Brackmann adds 20,000 shares at $11.59, you have to ask: do they know something Wall Street doesn’t? 🤔

Insider confidence is usually a good sign — especially when paired with Fidelity’s chunky 15% institutional stake. Yes, even the big dogs are leashed in. 🐕💰

🧪 What’s the Tech? Tumor Treating Fields (TTFields)

Forget chemo cocktails or gamma rays. Novocure is attacking cancer with… electric fields. ⚡🎛️

• TTFields = low-intensity, intermediate-frequency electric fields (100–500 kHz) that disrupt cancer cell division.

• Cancer cells get scrambled like eggs in a blender 🥚🥤 while healthy cells, which divide slowly and have different electrical properties, mostly shrug it off.

• Think of it as giving cancer a static-shock hairdo it can’t recover from. ⚡💇♂️

Applications already approved:

• Glioblastoma 🧠

• Non-small cell lung cancer (NSCLC) 🫁

• Malignant pleural mesothelioma 🫁

• Pleural mesothelioma 🫁

And the pipeline? Pancreatic cancer, brain metastases, and more — because if TTFields can play whack-a-mole with one tumor, why not two? 🎯🎯

🏦 Institutions Are All In

• Insiders: 9.81%

• Institutions: 86.45%

• Float held by institutions: 95.85%

Translation: retail investors barely get a chair at this poker table. 🃏

Top holders:

• FMR (Fidelity): 16.7M shares

• BlackRock: 14.1M shares

• Vanguard: 10.7M shares

When Wall Street’s holy trinity (FMR, BlackRock, Vanguard) all show up — it’s worth paying attention. 🔔

For Novocure (NVCR)'s Institutional Ownership breakdown, 🔍 see here

📊 Key Stats (2024–2025)

• Patients treated: 35,000+

• 2024 net revenues: $605M (+19% YoY)

• R&D spend: $210M (because curing cancer ain’t cheap)

• Q2 2025 revenues: $159M (+6% YoY)

• Active patients (Q2 2025): 4,331 globally

Pipeline = 🔥

• PANOVA-3: Pancreatic cancer Phase 3 → Best of ASCO 2025 🏆

• METIS: Brain metastases → FDA filing in H2 2025

• TRIDENT: Newly diagnosed glioblastoma → readout H1 2026

If this pipeline hits? TTFields could become the Swiss Army knife of oncology. 🔪🩺

💵 Financial Health

• Cash: $911M

• Cash burn: ~$50M per 6 months → ~9 years of runway! 🛫

• Gross margin: 74% (down from 77%, thanks tariffs & product rollout)

• Net loss Q2 2025: $40M (yes, still losing money… but it’s biotech)

Valuation measures (6/30/2025):

• Market cap: $1.41B

• EV/Revenue: 1.9x (cheap for biotech!)

• Shares down 94.5% from ATH of $232 (June 2021). 🪂

Translation: If TTFields works out, this could be the “shock therapy” investors actually enjoy. ⚡📈

👉 Want the full picture? Dive into Novocure (NVCR)'s financials here.

🌟 Why Bulls Like It

1. Tech moat: Proprietary TTFields platform. Competitors can’t just copy-paste electric fields like a playlist.

2. Pipeline optionality: From brain to pancreas, this tech is stretching across multiple cancers.

3. Runway: With 9 years of cash (assuming similar cash burn rates), they have the luxury of time to make this work.

4. Institutional conviction: Fidelity’s 15% stake is rare in biotech. 🏦

5. Insider buys: CEO + CFO literally put money where their electrodes are.

🐻 Why Bears Worry

1. Still unprofitable: Losses stack up faster than Netflix episodes (although they may decelerate over the next few quarters). 📉🍿

2. Dilution risk: If shares stay low, raising capital = painful dilution.

3. Clinical risk: TTFields are promising but still experimental in many indications. Adverse events (skin irritation, ulcers) are known.

4. Oncology is crowded: Radiation, chemo, immunotherapy, CAR-T, gene editing — TTFields is fighting for space.

5. Regulatory hurdles: Submissions to FDA/EMA take years, with no guarantees.

6. Reimbursement issues: Until insurance covers more, margins suffer when Novocure treats patients “at risk.”

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

🎬 Investment Take

• High risk, high reward biotech.

• Attractive entry point — stock trades 94% below ATH, institutions + insiders are buying, cash runway is long.

• But — if trials flop or regulators balk, shares could shock in the wrong direction. ⚡😬

🧾⚠️📢 Disclaimer: 🧾⚠️📢

We love the idea of zapping cancer with electric fields, but we’re not oncologists or financial advisors. Investing in Novocure may still get bumpy. 🎢

Always DYOR, hold the FOMO, and don’t invest what you can’t afford to lose.

We laugh, we analyze, we meme. We sell jokes and opinions — and yes, we’re billing your sense of humor. 🎪💸 
We’re not financial advisors. We’re FUNancial advisors. 

Invest at your own risk.

👉 Fun fact: If Novocure succeeds, you’ll want to tell people you read about “electrocuting cancer cells” before it was cool.

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny